1. Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment
- Author
-
Anne Le, Yi Hsuan Huang, Chun Chia Cheng, Chi Long Chen, Emily Elizabeth Evans, Yao An Shen, Cissy Zhang, and Ya Jie Chuang
- Subjects
0301 basic medicine ,Drug ,Combination therapy ,media_common.quotation_subject ,Glutamine ,Citric Acid Cycle ,Antineoplastic Agents ,Apoptosis ,Drug resistance ,010402 general chemistry ,01 natural sciences ,Biochemistry ,Article ,Analytical Chemistry ,03 medical and health sciences ,Glutaminase ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Animals ,Humans ,Lactic Acid ,Enzyme Inhibitors ,Glutaminolysis ,media_common ,business.industry ,Metabolic reprogramming ,Therapeutic resistance ,0104 chemical sciences ,Cancer treatment ,Clinical trial ,030104 developmental biology ,Drug Resistance, Neoplasm ,Cancer research ,Ketoglutaric Acids ,Drug Screening Assays, Antitumor ,business ,Glycogen ,Signal Transduction - Abstract
Targeting glutamine catabolism has been attracting more research attention on the development of successful cancer therapy. Catalytic enzymes such as glutaminase (GLS) in glutaminolysis, a series of biochemical reactions by which glutamine is converted to glutamate and then alpha-ketoglutarate, an intermediate of the tricarboxylic acid (TCA) cycle, can be targeted by small molecule inhibitors, some of which are undergoing early phase clinical trials and exhibiting promising safety profiles. However, resistance to glutaminolysis targeting treatments has been observed, necessitating the development of treatments to combat this resistance. One option is to use synergy drug combinations, which improve tumor chemotherapy's effectiveness and diminish drug resistance and side effects. This review will focus on studies involving the glutaminolysis pathway and diverse combination therapies with therapeutic implications.
- Published
- 2021